Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Nov 30;17(11):9263-9270.
doi: 10.21037/jtd-2025-1882. Epub 2025 Nov 26.

Immune checkpoint inhibitor resistance in non-small cell lung cancer: limits of vascular endothelial growth factor inhibition and new directions

Hiroyasu Kaneda  1
Affiliations
Editorial

Immune checkpoint inhibitor resistance in non-small cell lung cancer: limits of vascular endothelial growth factor inhibition and new directions

Hiroyasu Kaneda. J Thorac Dis. .
No abstract available

Keywords: Non-small cell lung cancer (NSCLC); immune checkpoint inhibitors (ICIs); resistance; tumor microenvironment (TME); vascular endothelial growth factor inhibition (VEGF inhibition).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-1882/coif). H.K. receives speaking and lecture fees from MSD, Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol Myers Squibb Co., and AstraZeneca. The author has no other conflicts of interest to declare.

Comment on

References

    1. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 2021;27:1345-56. 10.1038/s41591-021-01450-2 - DOI - PubMed
    1. Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227. J Clin Oncol 2023;41:1200-12. 10.1200/JCO.22.01503 - DOI - PMC - PubMed
    1. Garassino MC, Gadgeel S, Speranza G, et al. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study. J Clin Oncol 2023;41:1992-8. 10.1200/JCO.22.01989 - DOI - PMC - PubMed
    1. Novello S, Kowalski DM, Luft A, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol 2023;41:1999-2006. 10.1200/JCO.22.01990 - DOI - PMC - PubMed
    1. Peters S, Cho BC, Luft AV, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial. J Thorac Oncol 2025;20:76-93. 10.1016/j.jtho.2024.09.1381 - DOI - PubMed